Clinical Trial News

Regional Chemotherapy for Liver Metastases of Colorectal Cancer Shows Varied Perfusion Patterns

35 years ago

A study involving 82 patients with liver metastases from colorectal cancer treated with continuous chemotherapy via hepatic artery infusion pumps revealed varied liver perfusion patterns. While 70% of patients showed homogeneous liver perfusion, 24% had distinct inhomogeneities, and 6% exhibited selective perfusion of one hepatic lobe, impacting the response to therapy.

Regional Chemotherapy Shows Promise in Treating Colorectal Cancer Metastatic to the Liver

41 years ago

A study involving 93 patients with colorectal cancer metastatic to the liver treated with hepatic arterial infusion of 5-fluorodeoxyuridine (FUDR) showed significant tumor size reduction and prolonged survival, especially in patients without extrahepatic metastases.

D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial

Oncology Precision Medicine Targeted Therapy

110 years ago

A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.
The novel compound from D3Bio inhibits KRAS-G12C mutations at a faster rate and potentially longer duration than existing treatments, according to Dr. Herbert Loong from CUHK's Department of Clinical Oncology.
Researchers are planning phase 3 trials with the goal of positioning D3S-001 as a first-line treatment option for patients with KRAS-G12C-driven cancers of the lung, pancreas, and colon.

Home Terms & Conditions Privacy Policy